BRIEF published on 09/23/2026 at 21:41, 3 hours 46 minutes ago ABIONYX: 2026 Half-Year Results and Future Strategies Research And Development Treasury France 2030 ABIONYX Pharma 2026 Financial Results
BRIEF published on 09/23/2026 at 21:41, 3 hours 46 minutes ago ABIONYX Pharma Reports Half-Year Results for 2026 Financial Results Biopharmaceuticals Revenue Report LCAT Deficiency Sepsis Research
PRESS RELEASE published on 09/23/2026 at 21:36, 3 hours 51 minutes ago Inside Information / Other news releases ABIONYX Pharma announces half-year financial results for 2026 with emphasis on cash balance, revenue, and expenses. Focus on innovative therapies for sepsis and LCAT deficiency under France 2030 plan Half-year Results France 2030 Plan ABIONYX Pharma Sepsis LCAT Deficiency
BRIEF published on 08/27/2026 at 19:04, 27 days 6 hours ago ABIONYX Pharma Updates on Mid-Year 2026 Financials Cash Position Financial Update Ophthalmology ABIONYX Pharma 2026 Revenue
PRESS RELEASE published on 08/27/2026 at 18:59, 27 days 6 hours ago Inside Information / Other news releases ABIONYX Pharma updates activity and cash position for H1 2026: revenue of €1.9M, cash balance of €26.9M before Research Tax Credits and grants. Company focuses on innovative therapies for sepsis Revenue Cash Position Innovative Therapies ABIONYX Pharma Activity Update
BRIEF published on 07/06/2026 at 20:05, 2 months 17 days ago ABIONYX: Details on Share Capital and Voting Rights Euronext Paris Share Capital Voting Rights AMF ABIONYX
BRIEF published on 07/06/2026 at 20:05, 2 months 17 days ago ABIONYX Monthly Voting Rights Update Euronext Paris Share Capital Voting Rights Financial Update ABIONYX Pharma
PRESS RELEASE published on 07/06/2026 at 20:00, 2 months 17 days ago Inside Information / Other news releases ABIONYX Pharma discloses monthly statement of total voting rights and shares. Company focuses on innovative medicines development with lipid science expertise Shares Total Voting Rights ABIONYX Pharma Innovative Medicines Lipid Science
BRIEF published on 07/06/2026 at 19:19, 2 months 17 days ago ABIONYX's Half-Yearly Review of the Liquidity Contract Liquidity Transactions TP ICAP Actions ABIONYX Pharma
BRIEF published on 06/30/2026 at 19:13, 2 months 23 days ago ABIONYX Pharma Secures Funding to Advance Sepsis Treatment ABIONYX Pharma CER-001 Financial Funding Sepsis Treatment ApoA-I Platform
Published on 09/23/2026 at 22:00, 3 hours 27 minutes ago Petrolympic Adopts Semi-Annual Financial Reporting
Published on 09/23/2026 at 18:25, 7 hours 2 minutes ago Boba Mint Holdings Ltd. Reports Strong Early Subscription Adoption Following Soft Launch of Amino Pro
Published on 09/23/2026 at 15:42, 9 hours 45 minutes ago Global Atomic Announces C$50 Million Public Offering of Units
Published on 09/23/2026 at 14:31, 10 hours 56 minutes ago First Breach Completes First Untethered Flight of Proprietary Drone Prototype, Advancing American-Made Unmanned Systems Program
Published on 09/23/2026 at 14:30, 10 hours 57 minutes ago Phase II Clinical Trial of NV-387 as a Treatment for Monkeypox (MPox) Has Begun in DRC, Announces NanoViricides
Published on 09/23/2026 at 23:00, 2 hours 27 minutes ago Correction of a release from 23.09.2026 18:00 CET/CEST - MHM CORPORATE ANNOUNCES THE SUCCESS OF ITS CAPITAL INCREASE WITH PREFERENTIAL SUBSCRIPTION RIGHTS AND THE PARTIAL EARLY REDEMPTION OF BONDS REDEEMABLE IN SHARES
Published on 09/23/2026 at 19:51, 5 hours 35 minutes ago LIGHTON: LightOn renews its bond financing with the same financial partners for a maximum nominal amount of €4 million, and thus extends its cash flow horizon
Published on 09/23/2026 at 18:05, 7 hours 21 minutes ago XPRIZE Wildfire Awards $4.55M to Innovators Advancing Wildfire Detection and Response
Published on 09/23/2026 at 18:00, 7 hours 27 minutes ago ARVERNE GROUP: Release of the 2026 half-year financial report
Published on 09/23/2026 at 18:00, 7 hours 27 minutes ago ARVERNE GROUP: First half of 2026 60.1% growth in gross business volume to €16.8 million Operational performance above expectations
Published on 09/23/2026 at 19:14, 6 hours 12 minutes ago Robust performance from Investments and continued execution of the strategy
Published on 09/23/2026 at 17:45, 7 hours 42 minutes ago Report on share repurchases from 16 to 21 September 2026
Published on 09/23/2026 at 17:45, 7 hours 42 minutes ago Infotel : H1 2026 RESULTS. Revenue growth of +9.4%.
